225 related articles for article (PubMed ID: 26460249)
1. CEBPA copy number variations in normal karyotype acute myeloid leukemia: Possible role of breakpoint-associated microhomology and chromatin status in CEBPA mutagenesis.
Libura M; Pawełczyk M; Florek I; Matiakowska K; Jaźwiec B; Borg K; Solarska I; Zawada M; Czekalska S; Libura J; Salamanczuk Z; Jakóbczyk M; Mucha B; Duszeńko E; Soszyńska K; Karabin K; Piątkowska-Jakubas B; Całbecka M; Gajkowska-Kulig J; Gadomska G; Kiełbiński M; Ejduk A; Kata D; Grosicki S; Kyrcz-Krzemień S; Warzocha K; Kuliczkowski K; Skotnicki A; Jęrzejczak WW; Haus O
Blood Cells Mol Dis; 2015 Dec; 55(4):284-92. PubMed ID: 26460249
[TBL] [Abstract][Full Text] [Related]
2. Normal karyotype acute myeloid leukemia with the CD7+ CD15+ CD34+ HLA-DR + immunophenotype is a clinically distinct entity with a favorable outcome.
Iriyama N; Asou N; Miyazaki Y; Yamaguchi S; Sato S; Sakura T; Maeda T; Handa H; Takahashi M; Ohtake S; Hatta Y; Sakamaki H; Honda S; Taki T; Taniwaki M; Miyawaki S; Ohnishi K; Kobayashi Y; Naoe T
Ann Hematol; 2014 Jun; 93(6):957-63. PubMed ID: 24441947
[TBL] [Abstract][Full Text] [Related]
3. Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant.
Ahn JS; Kim JY; Kim HJ; Kim YK; Lee SS; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Minden MD; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
Ann Hematol; 2016 Jan; 95(2):301-10. PubMed ID: 26537612
[TBL] [Abstract][Full Text] [Related]
4. Combined testing for CCAAT/enhancer-binding protein alpha (CEBPA) mutations and promoter methylation in acute myeloid leukemia demonstrates shared phenotypic features.
Szankasi P; Ho AK; Bahler DW; Efimova O; Kelley TW
Leuk Res; 2011 Feb; 35(2):200-7. PubMed ID: 20970189
[TBL] [Abstract][Full Text] [Related]
5. Molecular evaluation of CEBPA gene mutation in normal karyotype acute myeloid leukemia: a comparison of two methods and report of novel CEBPA mutations from Indian acute myeloid leukemia patients.
Ahmad F; Rajput S; Mandava S; Das BR
Genet Test Mol Biomarkers; 2012 Jul; 16(7):707-15. PubMed ID: 22731647
[TBL] [Abstract][Full Text] [Related]
6. CEBPA gene mutations in Egyptian acute myeloid leukemia patients: impact on prognosis.
Awad MM; Aladle DA; Abousamra NK; Elghannam DM; Fawzy IM
Hematology; 2013 Mar; 18(2):61-8. PubMed ID: 22990006
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of CEBPA mutations and BAALC expression in acute myeloid leukemia Egyptian patients with normal karyotype.
El-Sharnouby JA; Ahmed LM; Taha AM; Kamal O
Egypt J Immunol; 2008; 15(1):131-43. PubMed ID: 20306678
[TBL] [Abstract][Full Text] [Related]
8. GATA2 mutations in patients with acute myeloid leukemia-paired samples analyses show that the mutation is unstable during disease evolution.
Hou HA; Lin YC; Kuo YY; Chou WC; Lin CC; Liu CY; Chen CY; Lin LI; Tseng MH; Huang CF; Chiang YC; Liu MC; Liu CW; Tang JL; Yao M; Huang SY; Ko BS; Hsu SC; Wu SJ; Tsay W; Chen YC; Tien HF
Ann Hematol; 2015 Feb; 94(2):211-21. PubMed ID: 25241285
[TBL] [Abstract][Full Text] [Related]
9. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
Bienz M; Ludwig M; Leibundgut EO; Mueller BU; Ratschiller D; Solenthaler M; Fey MF; Pabst T
Clin Cancer Res; 2005 Feb; 11(4):1416-24. PubMed ID: 15746041
[TBL] [Abstract][Full Text] [Related]
10. [CEBPA gene mutation analysis in acute myeloid leukemia].
Han C; Lin D; Ai XF; Wang F; Sun HY; Wang M; Mi YC; Wang JX; Ru K
Zhonghua Xue Ye Xue Za Zhi; 2013 Jul; 34(7):566-71. PubMed ID: 23906447
[TBL] [Abstract][Full Text] [Related]
11. Fragment length analysis screening for detection of CEBPA mutations in intermediate-risk karyotype acute myeloid leukemia.
Fuster O; Barragán E; Bolufer P; Such E; Valencia A; Ibáñez M; Dolz S; de Juan I; Jiménez A; Gómez MT; Buño I; Martínez J; Cervera J; Montesinos P; Moscardó F; Sanz MÁ
Ann Hematol; 2012 Jan; 91(1):1-7. PubMed ID: 21538063
[TBL] [Abstract][Full Text] [Related]
12. [Clinical characteristics and therapeutic efficacy of normal karyotype AML patients with CEBPA mutation].
Du YZ; Su L; Li W; Yu P; Tan YH; Lin H; Gao SJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Feb; 22(1):16-9. PubMed ID: 24598643
[TBL] [Abstract][Full Text] [Related]
13. Somatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemia.
Pabst T; Eyholzer M; Haefliger S; Schardt J; Mueller BU
J Clin Oncol; 2008 Nov; 26(31):5088-93. PubMed ID: 18768433
[TBL] [Abstract][Full Text] [Related]
14. K313dup is a recurrent CEBPA mutation in de novo acute myeloid leukemia (AML).
Carnicer MJ; Lasa A; Buschbeck M; Serrano E; Carricondo M; Brunet S; Aventin A; Sierra J; Di Croce L; Nomdedeu JF
Ann Hematol; 2008 Oct; 87(10):819-27. PubMed ID: 18587575
[TBL] [Abstract][Full Text] [Related]
15. Molecular genetic tests for FLT3, NPM1, and CEBPA in acute myeloid leukemia.
Zhang Q; Bai S; Vance GH
Methods Mol Biol; 2013; 999():105-21. PubMed ID: 23666693
[TBL] [Abstract][Full Text] [Related]
16. Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML.
Barjesteh van Waalwijk van Doorn-Khosrovani S; Erpelinck C; Meijer J; van Oosterhoud S; van Putten WL; Valk PJ; Berna Beverloo H; Tenen DG; Löwenberg B; Delwel R
Hematol J; 2003; 4(1):31-40. PubMed ID: 12692518
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.
Green CL; Koo KK; Hills RK; Burnett AK; Linch DC; Gale RE
J Clin Oncol; 2010 Jun; 28(16):2739-47. PubMed ID: 20439648
[TBL] [Abstract][Full Text] [Related]
18. Monoallelic CEBPA mutations in normal karyotype acute myeloid leukemia: independent favorable prognostic factor within NPM1 mutated patients.
Dufour A; Schneider F; Hoster E; Benthaus T; Ksienzyk B; Schneider S; Kakadia PM; Sauerland MC; Berdel WE; Büchner T; Wörmann B; Braess J; Subklewe M; Hiddemann W; Bohlander SK; Spiekermann K;
Ann Hematol; 2012 Jul; 91(7):1051-63. PubMed ID: 22362118
[TBL] [Abstract][Full Text] [Related]
19. [Analysis of CEBPA mutation in acute myeloid leukemia].
Zhang Y; Zhang SJ; Qiu HX; Qiao C; Sun HM; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Aug; 18(4):859-62. PubMed ID: 20723288
[TBL] [Abstract][Full Text] [Related]
20. Characterization of CEBPA mutations in acute myeloid leukemia: most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells.
Lin LI; Chen CY; Lin DT; Tsay W; Tang JL; Yeh YC; Shen HL; Su FH; Yao M; Huang SY; Tien HF
Clin Cancer Res; 2005 Feb; 11(4):1372-9. PubMed ID: 15746035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
